Fairvalue-Calculator Fairvalue-Calculator
EN DE

Tenax Therapeutics, Inc (TENX) Fair Value & Analysis

Healthcare · US · Market cap $325M

Price$13.64
Fair Value$16.47
Upside+20.7%
Quality95/100
Evidence: Low Range $12.35 – $20.59

Fair value as of: Jun 24, 2026

Analysis

Tenax Therapeutics, Inc (TENX) currently trades at $13.64, while our model-based Fair Value estimate is $16.47 — implying the stock looks roughly 20.7% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Chapel Hill, North Carolina.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Tenax Therapeutics, Inc (TENX) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $16.47 versus a price of $13.64 — about +21% (undervalued). Model-based estimate, not financial advice.
What is the fair value of TENX?
Our 21-model fair value for Tenax Therapeutics, Inc is $16.47 (as of Jun 24, 2026), built from audited fundamentals. The current price is $13.64.
What is the quality score of TENX?
Tenax Therapeutics, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.